PMID- 31410023
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 12
DP  - 2019
TI  - Retrospective analysis of sorafenib efficacy and safety in Chinese patients with 
      high recurrence rate of post-hepatic carcinectomy.
PG  - 5779-5791
LID - 10.2147/OTT.S168447 [doi]
AB  - Background: There is no guideline recommendation for preventing hepatocellular 
      carcinoma (HCC) recurrence after hepatic resection. Moreover, an unmet need 
      exists on the effectiveness of sorafenib therapy in recurrent HCC. Purpose: We 
      therefore assessed the efficacy and safety of sorafenib in Chinese HCC patients 
      with high risk of recurrence. Patients and methods: Data were collected 
      retrospectively from 15 Chinese research centers from January 1, 2012 to November 
      15, 2013, by chart reviews of patients with moderate-advanced HCC who received 
      hepatic carcinectomy. The primary end point was recurrence-free survival rate at 
      1 year in patients with a high recurrence risk. Secondary end points included 
      1-year survival rate, time to recurrence and safety assessment. Results: A total 
      of 209 high-risk patients (sorafenib, n=98; control, n=111) who underwent 
      carcinectomy were analyzed. There was no significant difference in the proportion 
      of patients with recurrence-free survival at 1 year between the sorafenib and 
      control (70.43% vs 68.90%: chi(2)=0.007, P=0.934). One-year survival rate was 
      significantly higher with sorafenib than observed with control (95.5% vs 83.35%; 
      chi(2)=7.441, P=0.006). Time to recurrence between sorafenib and control groups was 
      similar. Incidences of all the adverse events (AEs) were similar in both the 
      groups and transaminase elevation was most common in both groups (20.37% vs 
      24.79%). Thrombocytopenia incidence was significantly lower with the sorafenib 
      group than with control (1.85% vs 9.40%; P=0.015). Conclusion: Sorafenib may be 
      considered as a feasible option in the treatment of HCC recurrence.
FAU - Wang, Desheng
AU  - Wang D
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Shaanxi, China.
FAU - Jia, Weridong
AU  - Jia W
AD  - Department of Hepatobiliary Surgery, Anhui Provincial Hospital, Hefei, China.
FAU - Wang, Zhiming
AU  - Wang Z
AD  - Department of Hepatobiliary Surgery, Xiangya Hospital, Changsha, China.
FAU - Wen, Tianfu
AU  - Wen T
AD  - Department of Hepatobiliary Surgery, West China Hospital, Chengdu, China.
FAU - Ding, Wei
AU  - Ding W
AD  - Department of Hepatobiliary Surgery, Cancer Hospital of Xinjiang, Urumqi, China.
FAU - Xia, Feng
AU  - Xia F
AD  - Department of Hepatobiliary Surgery, Southwest Hospital, Chongqing, China.
FAU - Zhang, Ling
AU  - Zhang L
AD  - Department of Hepatobiliary Surgery, Cancer Hospital of Henan, Zhengzhou, China.
FAU - Wu, Feixiang
AU  - Wu F
AD  - Department of Hepatobiliary Surgery, Cancer Hospital of Guangxi Medical 
      University, Nanning, China.
FAU - Peng, Tao
AU  - Peng T
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi 
      Medical University, Nanning, China.
FAU - Liu, Bin
AU  - Liu B
AD  - Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming 
      Medical University, Kunming, China.
FAU - Zhou, Cuncai
AU  - Zhou C
AD  - Department of Hepatobiliary Surgery, Cancer Hospital of Jiangxi, Nanchang, China.
FAU - Zheng, Qichang
AU  - Zheng Q
AD  - Department of Hepatobiliary Surgery, Wuhan Union Hospital, Wuhan, China.
FAU - Miao, Xiongying
AU  - Miao X
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Xiangya, 
      Changsha, China.
FAU - Peng, Junping
AU  - Peng J
AD  - Department of Hepatopancreatobiliary Surgery, Cancer Hospital of Sichuan, 
      Chengdu, China.
FAU - Huang, Zhiyong
AU  - Huang Z
AD  - Department of Hepatobiliary Surgery, Wuhan Tongji Hospital, Wuhan, China.
FAU - Dou, Kefeng
AU  - Dou K
AD  - Department of Hepatobiliary Surgery, Xijing Hospital, Shaanxi, China.
LA  - eng
PT  - Journal Article
DEP - 20190717
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6643495
OTO - NOTNLM
OT  - Chinese
OT  - carcinectomy
OT  - hepatocellular carcinoma
OT  - recurrence
OT  - sorafenib
OT  - survival
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/08/15 06:00
MHDA- 2019/08/15 06:01
PMCR- 2019/07/17
CRDT- 2019/08/15 06:00
PHST- 2018/03/16 00:00 [received]
PHST- 2019/01/17 00:00 [accepted]
PHST- 2019/08/15 06:00 [entrez]
PHST- 2019/08/15 06:00 [pubmed]
PHST- 2019/08/15 06:01 [medline]
PHST- 2019/07/17 00:00 [pmc-release]
AID - 168447 [pii]
AID - 10.2147/OTT.S168447 [doi]
PST - epublish
SO  - Onco Targets Ther. 2019 Jul 17;12:5779-5791. doi: 10.2147/OTT.S168447. 
      eCollection 2019.